Zoetis Inc. Class A

165.90+2.87+1.76%Vol 1.59M1Y Perf -7.01%
May 26th, 2022 16:04 DELAYED
BID160.16 ASK167.60
Open163.83 Previous Close165.90
Pre-Market- After-Market165.90
 - -  - -%
Target Price
244.78 
Analyst Rating
Strong Buy 1.21
Potential %
47.55 
Finscreener Ranking
★★+     47.43
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★     45.42
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     63.87
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★     37.83
Price Range Ratio 52W %
9.97 
Earnings Rating
Sell
Market Cap78.08B 
Earnings Date
5th May 2022
Alpha0.01 Standard Deviation0.06
Beta0.77 

Today's Price Range

162.91166.57

52W Range

156.67249.27

5 Year PE Ratio Range

27.8072.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
2.05%
1 Month
-7.04%
3 Months
-14.80%
6 Months
-24.36%
1 Year
-7.01%
3 Years
62.01%
5 Years
164.97%
10 Years
-

TickerPriceChg.Chg.%
ZTS165.902.87001.76
AAPL143.783.26002.32
GOOG2 165.9249.13002.32
MSFT265.903.38001.29
XOM96.640.34000.35
WFC45.601.48003.35
JNJ179.46-0.1600-0.09
FB191.637.80004.24
GE77.012.48003.33
JPM129.442.20001.73
Financial StrengthValueIndustryS&P 500US Markets
1.40
2.30
0.54
1.45
12.50
Leverage Ratio 3.00
ProfitabilityValueIndustryS&P 500US Markets
70.60
34.80
40.60
28.40
26.27
RevenueValueIndustryS&P 500US Markets
7.89B
16.77
8.93
8.86
DividendsValueIndustryS&P 500US Markets
0.80
1.30
21.19
21.64
Payout ratio22.00
Earnings HistoryEstimateReportedSurprise %
Q01 20221.221.328.20
Q04 20210.961.004.17
Q03 20211.101.2513.64
Q02 20211.081.1910.19
Q01 20211.041.2621.15
Q04 20200.860.915.81
Q03 20200.891.1023.60
Q02 20200.660.8934.85
Earnings Per EndEstimateRevision %Trend
6/2022 QR1.22-7.58Negative
9/2022 QR1.31-2.24Negative
12/2022 FY5.06-1.75Negative
12/2023 FY5.79-0.86Negative
Next Report Date-
Estimated EPS Next Report1.22
Estimates Count8
EPS Growth Next 5 Years %11.80
Volume Overview
Volume1.59M
Shares Outstanding470.63K
Shares Float470.35M
Trades Count29.41K
Dollar Volume263.06M
Avg. Volume2.27M
Avg. Weekly Volume2.09M
Avg. Monthly Volume2.49M
Avg. Quarterly Volume2.24M

Zoetis Inc. Class A (NYSE: ZTS) stock closed at 165.9 per share at the end of the most recent trading day (a 1.76% change compared to the prior day closing price) with a volume of 1.59M shares and market capitalization of 78.08B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 11300 people. Zoetis Inc. Class A CEO is Kristin C. Peck.

The one-year performance of Zoetis Inc. Class A stock is -7.01%, while year-to-date (YTD) performance is -32.02%. ZTS stock has a five-year performance of 164.97%. Its 52-week range is between 156.67 and 249.27, which gives ZTS stock a 52-week price range ratio of 9.97%

Zoetis Inc. Class A currently has a PE ratio of 37.30, a price-to-book (PB) ratio of 16.42, a price-to-sale (PS) ratio of 9.72, a price to cashflow ratio of 36.40, a PEG ratio of 2.32, a ROA of 15.42%, a ROC of 19.69% and a ROE of 48.67%. The company’s profit margin is 26.27%, its EBITDA margin is 40.60%, and its revenue ttm is $7.89 Billion , which makes it $16.77 revenue per share.

Of the last four earnings reports from Zoetis Inc. Class A, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.22 for the next earnings report. Zoetis Inc. Class A’s next earnings report date is -.

The consensus rating of Wall Street analysts for Zoetis Inc. Class A is Strong Buy (1.21), with a target price of $244.78, which is +47.55% compared to the current price. The earnings rating for Zoetis Inc. Class A stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Zoetis Inc. Class A has a dividend yield of 0.80% with a dividend per share of $1.30 and a payout ratio of 22.00%.

Zoetis Inc. Class A has a Sell technical analysis rating based on Technical Indicators (ADX : 9.02, ATR14 : 4.74, CCI20 : -47.70, Chaikin Money Flow : -0.03, MACD : -5.49, Money Flow Index : 36.72, ROC : 0.75, RSI : 38.37, STOCH (14,3) : 43.35, STOCH RSI : 1.00, UO : 43.59, Williams %R : -56.65), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Zoetis Inc. Class A in the last 12-months were: Abhay U. Nayak (Option Excercise at a value of $0), Catherine A. Knupp (Sold 10 000 shares of value $2 171 900 ), Glenn David (Option Excercise at a value of $2 515 017), Glenn David (Sold 32 390 shares of value $6 149 880 ), Gregory Norden (Option Excercise at a value of $0), Gregory Norden (Sold 4 500 shares of value $972 315 ), Heidi C. Chen (Option Excercise at a value of $1 383 650), Heidi C. Chen (Sold 18 892 shares of value $4 063 858 ), Kristin C. Peck (Option Excercise at a value of $1 050 260), Kristin C. Peck (Sold 39 000 shares of value $8 109 348 ), Linda Rhodes (Option Excercise at a value of $0), Louise M. Parent (Option Excercise at a value of $0), Michael B. McCallister (Option Excercise at a value of $0), Paul M. Bisaro (Option Excercise at a value of $0), Robert J. Polzer (Option Excercise at a value of $0), Roman Trawicki (Option Excercise at a value of $1 006 393), Roman Trawicki (Sold 14 989 shares of value $2 841 952 ), Roxanne Lagano (Option Excercise at a value of $879 715), Roxanne Lagano (Sold 41 545 shares of value $8 404 376 ), Willie M. Reed (Option Excercise at a value of $0), Willie M. Reed (Sold 1 450 shares of value $300 295 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (83.33 %)
10 (76.92 %)
10 (76.92 %)
Moderate Buy
1 (8.33 %)
1 (7.69 %)
1 (7.69 %)
Hold
1 (8.33 %)
2 (15.38 %)
2 (15.38 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.21
Strong Buy
1.35
Strong Buy
1.35

Zoetis Inc. Class A

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

CEO: Kristin C. Peck

Telephone: +1 973 822-7000

Address: 10 Sylvan Way, Parsippany 07054, NJ, US

Number of employees: 11 300

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

64%36%

Bearish Bullish

59%41%

Bearish Bullish

60%40%

TipRanks News for ZTS

Sat, 07 May 2022 01:15 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (ZTS), BioCryst (BCRX) and McKesson (MCK)

- TipRanks. All rights reserved.

Wed, 16 Feb 2022 13:17 GMT Analysts Are Bullish on These Healthcare Stocks: Zoetis (ZTS), SAGE Therapeutics (SAGE)

- TipRanks. All rights reserved.

Wed, 16 Feb 2022 12:04 GMT Zoetis Q4 Earnings and Revenue Top Estimates Issues Guidance

- TipRanks. All rights reserved.

News

Stocktwits